Genmab A (GMAB) Operating Income (2018 - 2026)

Genmab A (GMAB) has reported Operating Income for 9 consecutive years, with $375.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income fell 31.57% year-over-year to $375.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.1 billion (up 20.57% YoY), and the FY2025 full-year result was $1.1 billion, up 9.57% from the prior year.
• Operating Income improved to $375.0 million in Q2 2026 per GMAB's latest filing, from $180.0 million in the prior quarter.
• Across five years, Operating Income topped out at $1.7 billion in Q3 2023 and bottomed at -$2.9 billion in Q4 2023.
• Historically, Operating Income has averaged $211.1 million across 5 years, with a median of $270.0 million in 2024.
• The widest YoY moves for Operating Income: up 152.11% in 2024, down 61.44% in 2024.
• Over 5 years, Operating Income stood at $127.1 million in 2022, then sank by 2364.72% to -$2.9 billion in 2023, then soared by 122.99% to $662.0 million in 2024, then jumped by 52.11% to $1.0 billion in 2025, then plunged by 62.76% to $375.0 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered $375.0 million, $180.0 million, and $1.0 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.